Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of CR6086 plus methotrexate in early rheumatoid arthritis
2016-004834-11Phase 2Completed
- Sponsor
- Rottapharm Biotech
- Start
- May 2017
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vorbipiprant in rheumatoid arthritis (RA) (4 arms), sponsored by Rottapharm Biotech. Primary endpoint: ACR20 responder rate. Started May 2017; status: completed.
02
Drugs
vorbipiprant
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-004834-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004834-11.